September 26, 2026

Timing of Stage 2 ROP May Help Identify High-Risk Eyes

In a study presented at Retina Society, stage 2 diagnosis at an earlier postmenstrual age was associated with higher treatment rates and a greater proportion of zone I disease.

September 26, 2026

New Tiespectus Data in Treatment-Naïve nAMD

Diana V. Do, MD, reviews phase 1/2a findings for the bispecific Tie2 agonist and VEGF inhibitor, presented at Retina Society 2026.

September 26, 2026

The Changing Economics of Retina

Twenty years of Medicare data show rising procedure volume, changing treatment patterns, and a 32% decline in inflation-adjusted reimbursement.

September 26, 2026

Avacincaptad Pegol and Anti-VEGF in Real-World Practice

An IRIS Registry analysis of more than 13,000 eyes found that concomitant anti-VEGF use for nAMD or CNV did not substantially alter complement inhibitor treatment.

September 25, 2026

Tracking Fluid Resolution After Photodynamic Therapy

A single-patient analysis found that more than half of estimated subretinal fluid volume resolved within 9 days of half-fluence PDT for chronic CSCR.

September 25, 2026

Epiretinal Membrane Removal May Reduce Injection Burden in nAMD

In a small retrospective study, two-thirds of patients stopped or reduced anti-VEGF injections following surgery.

September 25, 2026

Study Supports 30-Second Chlorhexidine Protocol for IVI

Aqueous chlorhexidine 0.05% significantly reduced conjunctival bacteria within 30 seconds, supporting a shorter antisepsis protocol using a less irritating alternative to povidone-iodine.

September 25, 2026

A First Look at the LUGANO Data

Charles C. Wykoff, MD, PhD, and Carl Regillo, MD, FACS, examine phase 3 EYP-1901 findings presented for the first time at Retina Society 2026.

September 25, 2026

New Data on Laru-Zova in XLRP

Phase 2 DAWN results provide additional evidence on safety and visual function as the laru-zova program advances through the pivotal VISTA trial.

September 25, 2026

Four-Year Data Show Durable MCO-010 Effect

Long-term follow-up of RESTORE participants shows sustained visual acuity improvements after a single intravitreal administration of the optogenetic therapy.